Author Affiliations University of Rochester, Medical Center, Rochester, USA Received: August 10, 2020 | Published: August 25, 2020 Corresponding author: Dr. Zaid Al Jebaje, Fellow of Cardiovascular Medicine, University of Rochester, Department on Medicine, Division of Cardiology, Rochester, NY, 601 Elmwood Avenue, Rochester, NY 14642, USA DOI: 10.26717/BJSTR.2020.29.004848 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID- 19) has had large implications in patients with preexisting cardiovascular conditions. COVID-19 has a high inflammatory burden which places patients at risk for developing repolarization changes with resultant prolongation of the QT syndrome and Torsades de Pointes (TdP). This is potentially further exacerbated by medications being used to treat COVID-19. However, there have been no cases of TdP reported without a specific link to medication during a COVID-19 infection. Abbreviations: ARDS: Acute Respiratory Distress Syndrome; ICU: Intensive Care Unit; CVD: cardiovascular disease; ACE2: Angiotensin-Converting Enzyme 2; CRS: Cytokine Release Syndrome; LQTS: Long QT Syndrome; SARS: Severe Acute Respiratory Syndrome; HERG: Human Ether- a-go-go-Related Gene